US20040057983A1 - Biomolecular wearable apparatus - Google Patents

Biomolecular wearable apparatus Download PDF

Info

Publication number
US20040057983A1
US20040057983A1 US10669596 US66959603A US2004057983A1 US 20040057983 A1 US20040057983 A1 US 20040057983A1 US 10669596 US10669596 US 10669596 US 66959603 A US66959603 A US 66959603A US 2004057983 A1 US2004057983 A1 US 2004057983A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
apparatus
subject
patch
biological effect
right
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10669596
Inventor
David Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soletluna Holdings Inc
Original Assignee
LIFEWAVE PRODUCTS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

This invention relates to an apparatus that regulates thermodynamic energy-flow within a human body for producing beneficial effects such as, for example, improvement in strength, improvement in stamina, pain relief, etc. According to one embodiment, the invention provides a wearable apparatus that may include biomolecular components for building-up of a thermomagnetic energy within the human body. According to another embodiment, the invention provides a wearable apparatus that may include biomolecular components for dilution of a thermomagnetic energy within the human body. According to yet another embodiment, the invention provides a wearable apparatus that may include biomolecular components having orthomolecular and/or non-orthomolecular organic materials which are capable of thermomagnetic levororotary action and/or thermomagnetic dextrorotatory action.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims priority from U.S. provisional patent application serial No. 60/413,617, filed on Sep. 25, 2002, which is incorporated by reference in its entirety.[0001]
  • FIELD OF THE INVENTION
  • This invention relates generally to a biomolecular wearable apparatus regulating energy-flow, and more particularly to a biomolecular wearable apparatus regulating thermomagnetic energy flow within human body for producing beneficial effects including an improvement in stamina and a relief from a pain. [0002]
  • BACKGROUND OF THE INVENTION
  • Jewelries including ring, necklace, bracelets, and pendants are typically used for decorative purpose. However, there is a segment of the jewelry market that concerns itself for a purpose other than decorative. Examples of jewelries that are designed for the purpose other than decorative include copper bracelets and magnetic jewelries. [0003]
  • Copper bracelet is believed to perform functions of relieving pain and helping to alleviate symptoms of arthritis for a user. A mode of operation for these functions has been proposed as mobility of copper ions from the copper bracelet through the user's skin and into the user's blood stream. If the mobility of copper ions is the mode of operation of a copper bracelet, then an individual or a user could not obtain immediate relief from pain, etc., due to a long period of time required for this mode of operation to become effective. Accordingly, a drawback of existing systems with respect to a copper bracelet is that the therapeutic response—if any—takes place over a relatively long period of time. Another drawback of the existing systems is that the copper bracelets have a limited and narrow field of use. [0004]
  • Various types of magnetic jewelries are believed to perform functions of relieving pain and improving circulation. Clinical studies performed with magnetic jewelries indicated that there is an effect going on other than a placebo effect. An effect of a magnet on a human body could be due, in part, to the fact that human blood contains iron. In one theory, the iron in the blood causes the blood to be attracted to a part of the body in which the magnet is worn, resulting in improvement in circulation. However, there are biophysicists who question the efficacy of a magnetic jewelry. For example, it is well known that the DNA contains Hydrogen bonds. Because a magnet is polar in nature, a back emf from the magnet to the Hydrogen bonds may be possible. This might cause the Hydrogen to spin in opposition to what is normal and disassemble the DNA of that cell. In any case, long term studies of magnets as they apply to humans are needed. Another drawback of the existing systems with respect to a magnetic jewelry, is that the therapeutic response—if any—is limited and narrow with respect to the field of use. [0005]
  • Therefore, with respect to jewelries that may be utilized for the purpose of achieving a therapeutic effect, there is a need for an alternative to the copper bracelet and the magnetic jewelries that are found in the present market. Such alternative may require a mode of operation that is different from the modes of operation of the existing copper bracelet and magnetic jewelries. In this regard, an examination of alternative modes of operation for a passive therapeutic jewelry needs to be considered. [0006]
  • First, referring to eastern philosophies, and specifically the Indian belief of a human CHAKRA SYSTEM, a representation of what is referred to in eastern medicine and philosophy as the human Chakra system is described. According to eastern philosophy, the human Chakras are points in the body in which a vortex-like flow reversal occurs, establishing a strong energy point in the human body. Like acupuncture, the concept of a “Chakra” system in human beings has not been embraced by conventional western medicine. However, it is interesting to note that the Chakra points do coincide with acupuncture points. Furthermore, the Chakra point of the Heart (#4, Anahata/Anandakanda) has special relevance to the invention disclosed here. [0007]
  • Referring now to publicly available HUMAN ACUPUNCTURE CHARTS, a representation of various human acupuncture and acupressure points are described. Unlike the “Chakra” concept, acupuncture has had some acceptance in western medicine, although this acceptance has only happened over a period of decades. As may be seen in Acupuncture Charts, there is a strong Chi (energy) point at the same point as the #4 Chakra. This is known as the Shanzhong point, and is indicative of the primary energy flow point in the human body. For further clarification, this point is located on the anterior midline, at the level of the fourth intercostals space. An additional point of interest is the Zhongji point, located 4 cun below the umbilicus, and is indicative of the crossing point of the ren channel. This is not to say that there are not additional points of interest in the acupuncture system. [0008]
  • Referring now to the work of Davis and Rawls (Magnetism and its effect on the living system by Albert Roy Davis and Walter C. Rawls, April 1996, Acres USA Publications), a view has been illustrated for actual electrical measurements made on the front surfaces of a human body. These measurements were performed by Albert Roy Davis and Walter Rawls at the Albert Roy Davis Research Laboratory in Florida. The findings of these two researchers indicate that the right side of the human body is positively (electrically) charged and the left side of the human body is negatively charged. These findings also indicate the average voltages that were recorded at various locations of the human body. It is worth noting that the vicinity of the #4 Chakra point shows the highest voltage among all the points on the human body. This would also coincide with the belief in the acupuncture system that the Shanzhong point is the strongest Chi point in the human body. [0009]
  • Referring again to Rawis and Davis (Magnetism and its effect on the living system by Albert Roy Davis and Walter C. Rawls, April 1996, Acres USA Publications), a view has been illustrated for the electromagnetic equators of the human body. Of interest with respect to the invention disclosed here is the point in the center of the chest, which Davis and Rawls state that according to their findings, this point is where voltage change is noted, and at this point there is zero voltage when measuring from the crotch to this point. Again, this corresponds well with the Chakra system and the acupuncture system. [0010]
  • In addition, the body of evidence supporting acupuncture has reached the point of being irrefutable. This said, a conclusion may be reached that in addition to blood flowing through the human body, there is also an energy flow through the human body. [0011]
  • In order to understand the energy flow through the human body, a phenomenon of a thermomagnetic field may need to be considered. A thermomagnetic field may be obtained when a group of dissimilar metals is arranged so as to form a coil, with each dissimilar metal junction being alternately heated and cooled. To illustrate this effect, reference is now made to the work of Schroeder, with publicly titled documents (U.S. Pat. No. 5,393,350 and U.S. Pat. No. 5,597,976) entitled THERMOELECTRIC GENERATOR AND MAGNETIC ENERGY STORAGE UNIT invented by Schroeder. In operation, this device is capable of obtaining a low voltage, high current within the ring structure resulting in a magnetic field of 10 to 20 tesla. The magnetic field produced is so strong that the ring requires structural reinforcement with Keviar or the like. The point made here is that this device produces a magnetic field in a novel manner, a method that does not use an electrical input but rather an input of heat. [0012]
  • Referring now to FIG. 1, a human body as illustrated relates to temperature differential. As illustrated in FIG. 1, human beings maintain a core temperature that is higher with respect to the extremities of the hands and feet. This differential is well known in the art and may be viewed in detail via infrared imaging techniques well known to those of skilled in the art. Due to this temperature differential as well as other factors, the conditions necessary for the production of thermomagnetic fields within the human body may be present. This phenomenon is scientifically plausible when one considers temperature differential, the presence of dissimilar metal components in the body such as Iron (blood) and Copper (collagen, enzymes, etc.), and the manner in which the blood flows via the circulatory system (flow reversals at extremities). In eastern philosophy, the thermomagnetic field is referred to as the “Aura”, and is shown to extend several inches from the body. This would be consistent with magnetism. Furthermore, Kirlian photography technique records a field of energy emanating several inches from humans and plants, again consistent with magnetic fields. [0013]
  • If there is indeed a magnetic energy field that extends from the surface of a human body, then it should be possible to construct a passive apparatus that would be capable of interacting with this field, and altering the properties of this field. As an example, in acupuncture, a practitioner utilizes known techniques to detect “blockages” to energy flows in the human body. When the locations of these blockages are determined, then either needles or pressure is applied to this point for the purpose of relieving and removing the blockages. Accordingly, another drawback of the existing systems is a lack of an apparatus that can be placed over specific acupuncture points and that can interact with a humans' energy field and promote energy flow and circulation in a similar mode of operation to acupuncture but without needles or physical contact. [0014]
  • When considering the flow of either fluids or energy, we now consider vortex flows that consist of either centripetal or centrifugal forces, and how these flows might be produced passively. As will be recalled, a vortex may have an inward spiraling flow (centripetal) or an outward spiraling flow (centrifugal). In nature, the tornado is an example of a phenomena that illustrates both flow types. Further, it is often stated that an inward spiraling vortex is associated with a build-up of energy, such as the destructive tip of the tornado, while an outward spiraling vortex is associated with a dilution of energy. [0015]
  • Various chemical species in the human body and biochemical materials may also need to be considered since they may play a role in interacting with energy fields within the human body. To this end, Left-Handed and Right-Handed molecules may need to be considered. It is known that the Left-Handed group of molecules known as amino acids are utilized in the body for the purpose of building protein structures such as muscle tissue. This process of the amino acid forming a “building block” for a larger protein structure is generally recognized as being a solely chemical process. However, if all naturally occurring amino acids are considered Left-Handed (amino acids are isomers and demonstrate the phenomena of optical chirality), and that light passing through an amino acid will bend to the left, a thermomagnetic field in the presence of an L-amino acid would orient itself to the left as well. Accordingly, at the molecular level, in the process of the amino acid being used to form a protein, the human thermomagnetic field twists to the left in the presence of the L-amino acid, causing the thermomagnetic field to spin clockwise (inward) which creates a buildup of energy, with this energy assisting in the formation of the new protein structure. [0016]
  • Similarly, some sugars such as sucrose may play a role in the human body. Common table sugar is a right-handed molecule. Thus, the human thermomagnetic field in the presence of sugar would spin counter-clockwise thereby creating a centrifugal flow which would lead to the dissipation of an energy field. This would at first seem to be inconsistent with the role that sugar plays in the body, which would be to create the basic building blocks of energy units (ATP). However, if we examine the actual chemical process that sugar is involved in, then we know that in order for sugar to enter the ATP cycle, it must first be broken down. Accordingly, at the molecular level, in the process of the sugar being broken down so that it may be used for the creation of ATP, the human thermomagnetic field twists to the right in the presence of the sugar, causing the thermomagnetic field to spin counter-clockwise (outward) which creates a dissipation of the structure, with this energy assisting in the destruction of the sugar molecule. [0017]
  • If these effects are occurring within the human body, then it should be possible to create a device that passively interacts with the human body in such a way so as to promote the build-up or flow of energy within the human body. [0018]
  • Therefore, another drawback of the existing system is a lack of an apparatus and a method for regulating the energy-flow, thereby producing a beneficial response within the human body. [0019]
  • These and other drawbacks also exist. [0020]
  • SUMMARY OF THE INVENTION
  • The invention overcomes these and other drawbacks. [0021]
  • In one embodiment, the invention provides an apparatus that produces a beneficial effect when placed on a human body. In some embodiments, the beneficial effect may include, for example, strength increase, stamina increase, pain relief, etc. [0022]
  • In one embodiment, the invention provides an apparatus that regulates thermomagnetic energy flow within a human body. [0023]
  • In one embodiment, the invention provides an apparatus that produces a beneficial effect when placed on a human body, wherein the apparatus regulates thermodynamic energy-flow within the human body for producing the beneficial effect. [0024]
  • In one embodiment, the invention provides an apparatus that includes biomolecular components for regulating thermomagnetic energy flow within a human body. In one embodiment, the biomolecular components may include molecules associated with building-up of energy (e.g., thermomagnetic energy). In another embodiment, the biomolecular components may include molecules associated with dilution of energy (e.g., thermomagnetic energy). In yet another embodiment, the biomolecular components may include molecules associated with building-up of energy (e.g., thermomagnetic energy) and dilution of energy (e.g., thermomagnetic energy). In a further embodiment, the biomolecular components may include orthomolecular and/or non-orthomolecular organic materials capable of thermomagnetic levororotary action and/or thermomagnetic dextrorotatory action. [0025]
  • In one embodiment, the invention provides an apparatus including biomolecular components associated with building-up of energy, wherein the biomolecular components may include, for example, but not limited to a Left-Handed molecule such as an amino acid (e.g., L-Glutamine). [0026]
  • In one embodiment, the invention provides an apparatus including biomolecular components associated with dilution of energy, wherein the biomolecular components may include, for example, but not limited to a Right-Handed molecule such as sugar, D-Glutamic acid, etc. [0027]
  • In one embodiment, the invention provides an apparatus including one or more substrates, for example, but not limited to a polyester, cotton fabric sheet, etc., for biomolecular components that regulate thermomagnetic energy flow within a human body. [0028]
  • In one embodiment, the invention provides an apparatus including a sealed plastic enclosure, wherein the sealed plastic enclosure may enclose biomolecular components regulating thermomagnetic energy flow within a human body and one or more substrates for the biomolecular components. [0029]
  • In one embodiment, the invention provides an apparatus that includes a sealed plastic enclosure having biomolecular components regulating thermomagnetic energy flow within a human body and one or more substrates for the biomolecular components, wherein the apparatus further includes one or more gem stones (e.g., Jade, powdered jade, etc.) for decorative purpose. [0030]
  • In one embodiment, the invention provides one or more physical structural settings for holding components of an apparatus. In some embodiments, said one or more physical structural settings may hold biomolecular components regulating thermomagnetic energy flow within a human body, one or more substrates for said biomolecular components, and one or more gem stones (e.g., Jade, powdered jade, etc.) for decorative purpose. [0031]
  • In one embodiment, the invention provides an apparatus that produces a beneficial effect, for example improvement in strength/stamina, when placed on a human body, wherein the apparatus may comprise one or more of components including, for example, Left-Handed molecules (e.g., L-Glutamine), one or more substrates (e.g., a polyester, cotton fabric sheet, etc.) for said Left-Handed molecules, a sealed enclosure (e.g., plastic film enclosure) enclosing said Left-Handed molecules and said one or more substrates, one or more gem stones or similar materials (e.g., jade, etc.). [0032]
  • In one embodiment, the invention provides an apparatus that produces a beneficial effect, for example relief from a pain, when placed on a human body, wherein the apparatus may comprise one or more of components including, for example, Right-Handed molecules (e.g., sucrose, D-Glutamic acid, etc.), one or more substrates (e.g., a polyester, cotton fabric sheet, etc.) for said Right-Handed molecules, a sealed enclosure (e.g., plastic film enclosure) enclosing said Right-Handed molecules and said one or more substrates, one or more gem stones or similar materials (e.g., jade, etc.). [0033]
  • In one embodiment, the invention provides an apparatus that may be in one or more of a plurality of wearable objects such as dermal patches, bracelets, pendants, support pads, shirts, socks, foot inserts, etc. [0034]
  • In some embodiments, the invention provides a non-transdermal patch having Left-Handed molecules for improving strength/stamina for a user. According to the invention, the non-transdermal patch having Left-Handed molecules may be manufactured with the following specifications: [0035]
  • 500 mg of L-Glutamine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glutamine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0036]
  • In other embodiments, the invention provides a non-transdermal patch having Right-Handed molecules for relieving from a pain for a user. According to the invention, the non-transdermal patch having Right-Handed molecules may be manufactured with the following specifications: Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0037]
  • In one embodiment, the invention provides a method for fabricating an apparatus that produces a beneficial effect when placed on a human body, wherein the apparatus regulates thermomagnetic energy-flow within the human body for producing the beneficial effect. [0038]
  • In one embodiment, the invention provides a method for placing an apparatus on a human body or into a human body, wherein the apparatus produces a beneficial effect when placed on the human body or into the human body, wherein the apparatus regulates thermomagnetic energy-flow within the human body for producing the beneficial effect. [0039]
  • Other objects and features of the invention will become apparent from the following detailed description considered in connection with the accompanying drawings that disclose embodiments of the invention. It should be understood, however, that the drawings are designed for purposes of illustration only and not as a definition of the limits of the invention.[0040]
  • BRIEF DESCRIPTIONS OF THE DRAWINGS
  • FIG. 1 illustrates temperature differential in a human body. [0041]
  • FIG. 2A illustrates an example of an apparatus including a single layer fabric substrate for retaining biomolecular components, according to an embodiment of the invention. [0042]
  • FIG. 2B illustrates an example of a sealed apparatus including a single layer fabric substrate for retaining biomolecular components, according to an embodiment of the invention. [0043]
  • FIG. 3A illustrates an example of an apparatus including a multi-layer fabric substrate for retaining biomolecular components, according to an embodiment of the invention. [0044]
  • FIG. 3B illustrates an example of a sealed apparatus including a multi-layer fabric substrate for retaining biomolecular components, according to an embodiment of the invention. [0045]
  • FIG. 4 illustrates an example of a patch including a biomolecular apparatus that causes a beneficial effect within a human body, according to an embodiment of the invention. [0046]
  • FIG. 5 illustrates an example of a bracelet including a biomolecular apparatus that causes a beneficial effect within a human body, according to an embodiment of the invention. [0047]
  • FIG. 6 illustrates an example of a ring including a biomolecular apparatus that causes a beneficial effect within a human body, according to an embodiment of the invention. [0048]
  • FIG. 7 illustrates an example of a watch including a biomolecular apparatus that causes a beneficial effect within a human body, according to an embodiment of the invention.[0049]
  • DETAILED DESCRIPTION OF THE INVENTION
  • According to one embodiment, the invention provides an apparatus that produces a beneficial effect when placed on a human body, wherein the apparatus regulates thermodynamic energy-flow within the human body for producing the beneficial effect. In some embodiments, the beneficial effect may include, for example, strength increase, stamina increase, and pain relief. [0050]
  • According to another embodiment, the invention provides an apparatus that may include biomolecular components for regulating thermomagnetic energy flow within a human body. In one embodiment, the biomolecular components may include molecules associated with building-up of energy (e.g., thermomagnetic energy). In another embodiment, the biomolecular components may include molecules associated with dilution of energy (e.g., thermomagnetic energy). In yet another embodiment, the biomolecular components may include molecules associated with building-up of energy (e.g., thermomagnetic energy) and dilution of energy (e.g., thermomagnetic energy). In a further embodiment, the biomolecular components may include orthomolecular (e.g., naturally occurring organic compounds) and/or non-orthomolecular organic materials capable of thermomagnetic levororotary action and/or thermomagnetic dextrorotatory action. [0051]
  • According to another embodiment, the invention provides an apparatus that may include orthomolecular organic compounds (e.g., naturally occurring organic compounds) and or non-orthomolecular organic compounds for inducing one or more beneficial effects such as, for example, strength increase, stamina increase, pain relief, etc. [0052]
  • Some of the orthomolecular and non-orthomolecular organic compounds may be more fully described as complex organic structures with asymmetric carbon atoms capable of either thermomagnetic levorotatory action due to the proton pulling forces associated with thermomagnetic fields or thermomagnetic dextrorotatory action due to the proton pulling forces associated with thermomagnetic fields. In both cases, according to one embodiment of the invention, the orthomolecular and/or nonorthomolecular organic materials utilized may be arranged parallel with respect to the plane of thermomagnetic rotation. [0053]
  • According to another embodiment, the invention provides an apparatus, wherein the apparatus functions on the basis of the principle that the proton pulling forces associated with human thermomagnetic fields are capable of interacting with passive orthomolecular and or non-orthomolecular organic materials so long as these materials are arranged parallel to the plane of rotation, with this arrangement inducing electron flow due to well known and long established electromotive principles. [0054]
  • It is known that hemoglobin is an Iron-containing pigment of red blood cells. Its function is to carry Oxygen from the lungs to other tissues. It is also known that collagen is a Copper containing, fibrous insoluble protein in connective tissues, including skin, bone, ligaments and cartilage. In addition, human beings possess a natural temperature differential from the core to the extremities. [0055]
  • In physics, the Seebeck effect describes a phenomena in which when an apparatus consists of two metals (such as Iron and Copper), with one metal at a higher temperature than the other, a current flows in the apparatus. The Thomson thermoelectric effect is the designation of the potential gradient along a conductor which accompanies a temperature gradient. [0056]
  • The thermomagnetic phenomena arises in that the thermoelectric and thermomagnetic power is measured by electromotive force produced by the unit difference of temperature, in this case the temperature differential from the core to the extremities. In short, all of the conditions necessary for human beings to produce thermomagnetic fields are present in humans. [0057]
  • According to another embodiment, the invention provides a passive apparatus that includes orthomolecular and non-orthomolecular organic compounds for improving one or more beneficial effects (e.g., strength, stamina, human performance, etc.) by interacting with a human thermomagnetic field. This interaction may induce an increased electron flow within a human body. In some embodiments, this interaction is not unlike the effect that occurs in an electrical generator in which electricity is produced from moving magnets or magnetic fields. [0058]
  • In humans, an increase in electron flow has numerous demonstrable benefits with one being an immediate and measurable increase in physical strength. This is not a chemically induced increase in strength such as would be the case with anabolic steroids, etc., but rather a phenomena in which existing muscle mass is utilized more efficiently due to the increase in electron flow. [0059]
  • To understand how this phenomena could be possible, if we examine the striated skeletal muscle apparatus we know that this voluntary group nerve supply is under conscious control because these nerves are branches of the peripheral cerebrospinal nervous apparatus (the brain and spinal cord as the cerebrospinal axis), The muscle fibers themselves are tissues composed of contractile cells that effect movement based on the excitatory process set up in nerve fibers by stimuli (the nerve impulse). It is presently believed by medical research that the nerve impulse is probably in the nature of a wave of electrochemical disturbances. The efficiency with which the nerve impulse controls a specific muscle group can be defined as the number of muscle fibers utilized in a contraction divided by the number of fibers present in that muscle group. It is presently believed that most humans only contract a small percentage of muscle fibers in a given group for a given nerve impulse (low efficiency of muscle mass usage per nerve impulse contraction). [0060]
  • If now we were to induce a condition in which the total power of the electrochemical nerve impulse could be increased so that more muscle fibers could contract for a given nerve impulse, the net efficiency of the striated fibers would increase (more muscle fibers in a group being contracted for a nerve impulse), and hence usable physical strength could be improved. This is one possible explanation for the phenomena associated with beneficial effects, for example, immediate and demonstrable increases in strength and stamina within seconds of wearing the wearable apparatus of the present invention. [0061]
  • This phenomena is not unusual or unknown in other devices. For example, in physical therapy electrical signals are utilized for the purpose of forcing voluntary muscle groups to contract under stimulation. These devices are commonly known as electrical or electronic muscle stimulators (EMS) and cause stimulated contraction and relaxation phases of muscle groups. According to another embodiment, the invention provides an apparatus for, based on the mode of operation as presented, an improvement in net efficiency of total muscle mass utilized during a contraction phase that may be achieved due to an increase in electron flow during the wave of electrochemical disturbances created by the nerve impulse. [0062]
  • According to another aspect, the invention provides an apparatus that passively modulates the oscillating low energy magnetic field that exists just above the surface of the human epidermal layer. This passive frequency modulation creates a condition in which the transport of long chain fatty acids across the mitochondrial membrane for subsequent beta-oxidation and energy production is triggered or improved, thereby providing a user of the apparatus with increased energy via an increase in ATP production as described above. [0063]
  • To understand this phenomenon, the metabolic process involving fatty acid energy sources within the human body can be examined. Fatty acids, a hydrocarbon in which one of the hydrogen atoms has been replaced by a carboxyl group, are also described as a monobasic aliphatic acid made up of an alkyl radical attached to a carboxyl group. The metabolic role of fatty acids may be described in part in that fatty acids are one of the primary sources of energy for humans and, through Beta-Oxidation, are broken down into basic units of energy. Of interest here is that, in order for this process to work, fatty acids need to enter the mitochondria for Beta-Oxidation, and they are unable to penetrate the inner mitochondrial membrane by themselves. In the human body, to overcome the problem of the inability of fatty acids to transport from the cytosol (soluble portion of the cell) across the mitochondrial membrane, it has been determined by several researchers that various nutrients are essential to transport long chain fatty acids from the cytosol across the mitochondrial membrane for fatty acid oxidation/metabolism and energy production. [0064]
  • According to the invention, in order to obtain the desirable effect of improving cell metabolism passively (specifically, increasing the rate of fatty acid Beta-Oxidation by allowing fatty acids to transport across the mitochondrial membrane), an apparatus consisting of orthomolecular organic structures can be designed to passively interact with the human magnetic field for the purpose of creating a system of frequency modulation, much in the same way that radio waves are modulated to communicate audio information. [0065]
  • According to an embodiment of the invention, an apparatus [0066] 100 that causes a beneficial effect by regulating thermomagnetic energy-flow within a human body are illustrated in FIGS. 2A, 2B, 3A, and 3B.
  • According to another embodiment, the invention provides apparatus [0067] 100 comprising biomolecular components that may include molecules associated with building-up of energy (e.g., thermomagnetic energy). In some embodiments, biomolecular components may include a Left-Handed molecule such as, for example, an amino acid. In one embodiment, the apparatus may include a structure that may be used for promoting the flow of energy (electrons) within a human body so as to improve physical strength of a user, wherein the structure may include a Left-Handed molecule such as, for example, an amino acid.
  • The Left-Handed amino acids are known in those skilled in the art, and as such a complete description of the Left-Handed amino acids need not be given here, but suffice it to say that suitable Left-Handed amino acids for use in the invention may include, for example, L-Glutamine, L-Arginine, L-Ornithine, L-Camitine, L-Taurine, L-Tryptophan, L-Glycine, etc. Preferably, the amino acids used in the invention are orthomolecular amino acids. [0068]
  • In some embodiments, the Left-Handed molecule is an amino acid found in nature. In other embodiments, the Left-Handed molecule is an amino acid synthesized by man. The examples of amino acids may include, but not limited to, L-Alanine, L-Arginine, L-Aspargine, L-Aspartic Acid, L-Carnitine, Acetyl-L-Carnitine, L-Camitine L-Tartrate, L-Camitine Magnesium Citrate, L-Citrulline, L-Cystine, L-Cystine, L-GABA, L-Glutamic Acid, L-Glutamine, Glutathione Peroxidase, L-Glycine, L-Histidine, Hydroxyglutamic Acid, Hydroxyproline, L-Isoleucine, L-Leucine, Norleucine, L-Lysine, L-Methionine, L-Omithine, L-Valine, L-Phenylalanine, L-Proline, L-Serine, L-Taurine, L-Threonine, L-Tryptophan, L-Tyrosine, etc. In some embodiments, the Left-Handed molecules may include a synthetic L-sugar (L-glucose) or other synthetic levo-rotatory molecule known to one skilled in the art. [0069]
  • According to another embodiment of the invention, the Left-Handed molecule may be employed in a variety of ways. In one example, the biomolecular components including the Left-Handed molecules may be used in the form of a liquid, with said liquid being sprayed or similarly applied to a substrate. In another example, the biomolecular components including the Left-Handed molecule may be used in the form of a solid, such as a powder, with said powder being mixed with a binder such as latex rubber, silicone rubber, epoxy, wax or the like, with the powdered amino acid and binder being applied to a substrate. [0070]
  • According to another embodiment, the invention may include a structure that includes a plurality of Left-Handed molecules. In other words, more than one kind of Left-Handed molecules may be utilized in a structure. In one example, a structure in which L-glutamine may be applied to a single substrate, followed by the layering of a second amino acid such as L-Arginine to a second substrate, with both treated substrates forming part of the completed structure of the invention. In some embodiments, portions of L-Glutamine and L-Arginine may be mixed together, and then applied in the form of a liquid or powder to a single substrate. In another example, two or more L amino acids may be applied to the same substrate. [0071]
  • According to another embodiment, the invention provides an apparatus comprising biomolecular components that may include molecules associated with dilution of energy (e.g., thermomagnetic energy). In some embodiments, the biomolecular components may include Right-Handed molecules such as, for example, an amino acid. In one embodiment, the apparatus may include a structure that may be used for negating flow of energy (electrons) within a human body so as to decrease physical strength of a user or relax the user, wherein the structure may include Right-Handed molecules such as, for example, an amino acid or sugar. [0072]
  • The Right-Handed amino acids and Right-Handed sugars are known to those skilled in the art, and as such a complete description of these materials need not be given here, but suffice it to say that suitable Right-Handed amino acids (i.e., D amino acids) for use in the present invention may include, for example, D-Glutamine, D-Arginine, D-Ornithine, D-Camitine, D-Taurine, D-Tryptophan, D-Glycine, D-Glutamic Acid, etc. [0073]
  • In some embodiments, the Right-Handed molecule is an amino acid found in nature. In other embodiments, the Right-Handed molecule is an amino acid synthesized by man. The Examples of the Right-Handed molecule may include, but not limited to, D-Alanine, D-Arginine, D-Aspargine, D-Aspartic Acid, D-Camitine, Acetyl-D-Camitine, D-Camitine D-Tartrate, D-Camitine Magnesium Citrate, D-Citrulline, D-Cysteine, D-Cystine, D-GABA, D-Glutamic Acid, D-Glutamine, D-Glutathione Peroxidase, D-Glycine, D-Histidine, D-Hydroxyglutamic Acid, D-Hydroxyproline, D-Soleucine, D-Leucine, D-Norleucine, D-Lysine, D-Metbionine, D-Omithine, D-Valine, D-Phenylalanine, D-Proline, D-Serine, D-Taurine, D-Threonine, D-Tryptophan, D-Tyrosine, etc. [0074]
  • According to another embodiment, the Right-Handed molecules may include one or more sugars, for example, but not limited to dextrin, dextrose, fructose, galactose, glucose, glycogen, high fructose corn syrup, honey, inositol, invert sugar, lactose, levulose, maltose, molasses, sucrose, sugar cane, and xylose etc. Preferably, the Right-Handed amino acids used in the invention are non-orthomolecular amino acids. [0075]
  • According to another embodiment of the invention, the Right-Handed molecules may be employed in a variety of ways. In one example, the biomolecular components including the Right-Handed molecules may be used in the form of a liquid, with said liquid being sprayed or similarly applied to a substrate. In another example, biomolecular components including the Right-Handed molecules may be used in the form of a solid, such as a powder, with said powder being mixed with a binder such as latex rubber, silicone rubber, epoxy, wax or the like, with the powdered amino acid and binder being applied to a substrate. [0076]
  • According to another embodiment, the invention may include a structure that includes a plurality of Right-Handed molecules. In other words, more than one kind of Right-Handed molecules may be used in a structure. In one example, a structure in which D-Glutamic acid may be applied to a single substrate, followed by the layering of a second D amino acid to a second substrate, with both treated substrates forming part of the completed structure of the invention. In some embodiments, portions of D-Glutamc acid and a second D amino acid may be mixed together, and then applied in the form of a liquid or powder to a single substrate. In another example, two or more D amino acids may be applied to the same substrate. [0077]
  • According to another embodiment, the invention provides an apparatus including one or more substrates for the biomolecular components regulating thermomagnetic energy flow within a human body. In some embodiments, the one or more substrates may include, for example, but not limited to a polyester fabric sheet, a cotton fabric sheet, etc. In one embodiment, the one or more substrates may be used for the Left-Handed molecules. In another embodiment, the one or more substrates may be used for the Right Handed molecules. The one or more substrates may not react (chemically, etc.) with the Left-Handed molecules and the Right-Handed molecules of the invention. The examples of substrates may include, for example, but not limited to polyester fabric sheet (e.g., manufactured by Pellon, # 910, an interfacing material for lightweight to featherweight fabrics, etc.), cotton fabric sheet, etc. In one embodiment, either the polyester fabric sheet or the cotton fabric sheet may be used in construction of the apparatus of the invention. In another embodiment, both the polyester fabric sheet and the cotton fabric sheet may be used in construction of apparatus [0078] 100 of the invention.
  • According to another embodiment, the invention may include one or more additives for the Left-Handed molecules and/or Right-Handed molecules. The examples of additives may include, but not limited to Glycerin, d-calcium pantothenate, sorbitol, propylparaben, potassium sorbate, methylparaben, Colloidal Gold, etc. [0079]
  • According to another embodiment, the invention provides an apparatus including a sealed enclosure, wherein the sealed enclosure may enclose biomolecular components (e.g., Left-Handed molecules, Right-Handed molecules) regulating thermomagnetic energy flow within the human body and one or more substrates for the biomolecular components. The sealed enclosure may be made of a material, for example, but not limited to a polyester film sheet (e.g., manufactured by GBC, a thermal laminating film, etc.), a plastic film (e.g., polyethylene, polypropylene, ABS, plexiglass, lexan, pvc, etc), etc. In one embodiment, the polyester film sheet and/or the plastic film may be utilized in construction of the apparatus of the invention. In some embodiments the sealed enclosure may be made of a light polarizing film. In other embodiments the sealed enclosure may be made of a linear low density film. [0080]
  • According to another embodiment of the invention, the sealed enclosure may not react (i.e., chemically, etc.) with biomolecular components (e.g., Left-Handed molecules, Right-Handed molecules) of the invention. In some embodiments, the sealed enclosure may be capable of being sealed in a predefined fashion to keep the Left-Handed molecules and/or the Right-Handed molecules in a liquid state. In some embodiments, the sealed enclosure may be capable of being sealed in a predefined fashion to protect the Left-Handed molecules and/or the Right-Handed molecules from ambient environmental conditions. [0081]
  • Methods of sealing plastic films are known to those skilled in the art and will not be described here in detail. Examples of such methods of sealing plastic films may include, for example, pressure sensitive or thermally sensitive adhesives, ultrasonic sealing, etc. [0082]
  • According to another embodiment, the invention provides an apparatus that includes a sealed plastic enclosure that encloses biomolecular components regulating thermomagnetic energy flow within the human body and one or more substrates for the biomolecular components, wherein the apparatus further includes one or more gem stones (e.g., Jade, powdered jade, etc.). [0083]
  • In one embodiment, Jade may be used for decorative purposes, and for the practice of the invention. Jade (or other gem stones) may be incorporated into the invention in either gem stone form, or in powdered form. If Jade is incorporated in stone form, then the apparatus of the invention may be embodied as decorative items such as jewelry, etc. If Jade is incorporated in powdered form, then the Jade powder may be added to the Left-Handed molecules and/or the Right-Handed molecules. The Jade may also be added in other parts of the devices of the invention so as to make the apparatus practical for use. [0084]
  • According to another embodiment, the invention provides one or more physical structural settings for holding one or more components of apparatus [0085] 100. In some embodiments, that the one or more physical structural settings may hold biomolecular components regulating thermomagnetic energy flow within the human body, one or more substrates for the biomolecular components, and one or more gem stones (e.g., Jade, powdered jade, etc.).
  • According to another embodiment, apparatus [0086] 100 may be in one or more of a plurality of wearable objects, for example, but not limited to dermal patches, bracelets, pendants, support pads, shirts, socks, foot inserts, etc.
  • According to another embodiment, the invention may include a patch having an adhesive (e.g., medical grade adhesive). In some embodiments, the invention may include a single patch. In other embodiments, the invention may include a plurality of patches. In one embodiment, the patch may be constructed in layers made of plastic film or light polarizing film, polyester fabric as a substrate, Water, L-Camitine, Glycerin, d-calcium pantothenate, sorbitol, propylparaben, potassium sorbate, and methylparaben. In another embodiment, the patch may be constructed in layers made of a plastic film or a light polarizing film as an enclosure, a polyester fabric as a substrate, Honey and Molasses. [0087]
  • If apparatus [0088] 100 of the present invention is embodied as jewelry items, then the apparatus may be mounted in virtually any jewelry setting that is already commercially available, provided that the setting does not interfere in any way with the operation of apparatus 100 of the present invention. If apparatus 100 of the invention is embodied in “Band Aid” style or “Transdermal Patch” style, then a setting would not be needed. In one embodiment, apparatus 100 of the invention may be completely sealed, thereby the Left-Handed molecules and/or the Right-Handed molecules may not make direct contact with a user of apparatus 100. In addition, the Left-Handed molecules and/or the Right-Handed molecules may not enter into body of the user.
  • In some embodiments, Apparatus [0089] 100 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Glutamine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glutamine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0090]
  • In other embodiments, Apparatus [0091] 100 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0092]
  • According to another embodiment, the invention provides a method for placing apparatus [0093] 100 on a predetermined location of a human body or into a human body, wherein apparatus 100 produces a beneficial effect when placed on the human body or into the human body, wherein apparatus 100 regulates thermodynamic energy-flow within the human body for producing the beneficial effect. The apparatus 100 may include, for example, patch, bracelet, necklace, anklet, etc.
  • According to another embodiment, the invention provides methods for placing apparatus [0094] 100 of the invention into proximity of a human body. In one example, apparatus 100 of the invention may be attached to pendants, and allowed to be placed into proximity of the human body. In another example, apparatus 100 of the invention may be embodied in “Band Aid” style or “Patch” style, with a medical grade adhesive being applied to the device to make it suitable for use with human beings.
  • In one embodiment, apparatus [0095] 100 (e.g., dermal patch) may be placed on forearms of a user for producing a beneficial effect such as, for example, improvement in strength or stamina. In some embodiments, apparatus 100 (e.g., dermal patch) having Left-Handed molecules may be placed on the palm side of the right forearm of the user. In other embodiments, apparatus 100 (e.g., dermal patch) having Right-Handed molecules may be placed on the palm side of the left forearm of the user.
  • For strength and stamina, apparatus [0096] 100 (e.g., dermal patch) may be placed at Pericardium 4 (P4) located about 4 inches below the wrist.
  • For relief of sinus congestion, apparatus [0097] 100 (e.g., dermal patch) may be placed on Large Intestine 14 (LI 14). In some embodiments, apparatus 100 (e.g., dermal patch) having Left-Handed molecules may be placed on RIGHT shoulder and apparatus 100 (e.g., dermal patch) having Right-Handed molecules may be placed on left shoulder for relief of sinus congestion.
  • For relief of menstrual cramps, woman may place apparatus [0098] 100 (e.g., dermal patch) having Left-Handed molecules at the depression on the midline of the chest and apparatus 100 (e.g., dermal patch) having Right-Handed molecules at about 1-2 inches below the belly button (where the cramps are).
  • For relief of knee pain from arthritis, apparatus [0099] 100 (e.g., dermal patch) having Left-Handed molecules may be placed along the midline at the depression between the chest and apparatus 100 (e.g., dermal patch) having Right-Handed molecules may be placed where the pain is on the knee.
  • In a preferred embodiment, apparatus [0100] 100 (e.g., dermal patch) having Left-Handed molecules may be placed at an electrically POSITIVE point on the body and apparatus 100 (e.g., dermal patch) having Right-Handed molecules may be placed at an electrically NEGATIVE point on the body. Positive and Negative points on the body have been metered and been well known by physiologists for about 30 years+.
  • Furthermore, apparatus [0101] 100 (e.g., dermal patch) may be placed at known acupuncture points. For example, apparatus 100 having Left-Handed molecules (e.g., POSITIVE dermal patch) may be placed at a YANG (positive) point and apparatus 100 (e.g., dermal patch) having Right-Handed molecules (e.g., NEGATIVE dermal patch) may be placed at a TIN (negative) point.
  • According to another embodiment of the invention illustrated in FIG. 2A, apparatus [0102] 100 that causes a beneficial effect (e.g., improvement in strength/stamina, relief from a pain, etc.) by regulating thermomagnetic energy flow within a human body may include a single layer fabric substrate 110 for retaining biomolecular components including, for example, molecules for building-up of energy (e.g., thermomagnetic energy) and/or molecules for dilution of energy (e.g., thermomagnetic energy). Apparatus 100, as illustrated, may be fabricated in accordance with the principles as described here in the preceding disclosure.
  • FIG. 2B illustrates a sealed single layer fabric substrate that retain the biomolecular components. [0103]
  • According to another embodiment of the invention illustrated in FIG. 3A, apparatus [0104] 100 that causes a beneficial effect (e.g., improvement in strength/stamina, relief from a pain, etc.) by regulating thermomagnetic energy-flow within a human body may include two layers of fabric substrate 120 for retaining biomolecular components including, for example, molecules for building-up of energy (e.g., thermomagnetic energy) and/or molecules for dilution of energy (e.g., thermomagnetic energy). Apparatus 100, as illustrated, may be fabricated in accordance with the principles as described here in the preceding disclosure.
  • FIG. 3B illustrates a sealed multi layer fabric substrate that retain the biomolecular components. [0105]
  • According to another embodiment of the invention illustrated in FIG. 4, a patch [0106] 400 may include apparatus 100 for causing a beneficial effect (e.g., improvement in strength/stamina, relief from a pain, etc.) for a human body by regulating thermomagnetic energy flow within the human body. In some embodiments, one or more portions of patch 400 may include medical grade adhesive for enabling attachment of patch 400 to human skin surface.
  • According to another embodiment of the invention illustrated in FIG. 5, a bracelet [0107] 500 may include apparatus 100 for causing a beneficial effect (e.g., improvement in strength/stamina, relief from a pain, etc.) for a human body by regulating thermomagnetic energy flow within the human body. In some embodiments, bracelet 500 may also include a gem stone (not shown in FIG. 5).
  • According to another embodiment of the invention illustrated in FIG. 6, a ring [0108] 600 may include apparatus 100 for causing a beneficial effect (e.g., improvement in strength/stamina, relief from a pain, etc.) for a human body by regulating thermomagnetic energy flow within the human body. In some embodiments, ring 600 may also include a gem stone 610.
  • According to another embodiment of the invention illustrated in FIG. 7, a watch [0109] 700 may include apparatus 100 for causing a beneficial effect (e.g., improvement in strength/stamina, relief from a pain, etc.) for a human body by regulating thermomagnetic energy flow within the human body.
  • EXAMPLES Example 1
  • Patch [0110] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Carnitine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. The interfacing material is dipped in the L-Carnitine solution so as to saturate the fabric with the solution. The saturated fabric disk is then sandwiched and placed between 2 layers of the heat laminating film, and the structure is sealed with a heating surface so as to form the completed structure. [0111]
  • Patch [0112] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) is utilized as the patch ingredient. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. The interfacing material is dipped in the Honey so as to saturate the fabric with the solution. The honey-saturated fabric disk is then sandwiched and placed between 2 layers of the heat laminating film, and the structure is sealed with a heating surface so as to form the completed structure. [0113]
  • The above patches were tested with users by placing patch [0114] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 15% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches.
  • Example 2
  • Patch [0115] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Camitine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Camitine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0116]
  • Patch [0117] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0118]
  • The above patches were tested with users by placing patch [0119] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 15% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches. This formulation was utilized in the Morehouse College Clinical Study and the Troy State University Clinical Study.
  • Example 3
  • Patch [0120] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Glutamine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glutamine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0121]
  • Patch [0122] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0123]
  • The above patches were tested with users by placing patch [0124] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 15% on average when using this formulation as opposed to not using these patches.
  • Example 4
  • Patch [0125] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Camitine is added to 15 ml of distilled water; To this solution small amounts of preservatives are added so as to prevent the formation of mold or bacteria. In this case the preservatives that are added are glycerin, potassium sorbate, methylparaben and propylparaben. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glutamine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0126]
  • Patch [0127] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredients. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0128]
  • The above patches were tested with users by placing patch [0129] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 15% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches.
  • Example 5
  • Patch [0130] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Glutamine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glutamine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0131]
  • Patch [0132] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0133]
  • The above patches were tested with users by placing patch [0134] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 15% on average when using this formulation as opposed to not using these patches.
  • Example 6
  • Patch [0135] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of acetyl-L-Carnitine is added to 15 ml of glycerin; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the acetyl-1-carnitine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0136]
  • Patch [0137] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0138]
  • The above patches were tested with users by placing patch [0139] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 15% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 25% on average when using this formulation as opposed to not using these patches.
  • Example 7
  • Patch [0140] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of acetyl-1-carnitine and 100 mg of L-Omithine are added to 30 ml of glycerin; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the amino acid solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0141]
  • Patch [0142] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0143]
  • The above patches were tested with users by placing patch [0144] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 15% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 25% on average when using this formulation as opposed to not using these patches.
  • Example 8
  • Patch [0145] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of acetyl-1-carnitine and 100 mg of L-Arginine are added to 30 ml of glycerin; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the amino acid solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0146]
  • Patch [0147] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0148]
  • The above patches were tested with users by placing patch [0149] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 15% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 25% on average when using this formulation as opposed to not using these patches.
  • Example 9
  • Patch [0150] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Arginine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Arginine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0151]
  • Patch [0152] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0153]
  • The above patches were tested with users by placing patch [0154] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches.
  • Example 10
  • Patch [0155] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Ornithine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Ornithine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0156]
  • Patch [0157] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0158]
  • The above patches were tested with users by placing patch [0159] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches.
  • Example 11
  • Patch [0160] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Glutamic Acid is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glutamic Acid solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0161]
  • Patch [0162] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0163]
  • The above patches were tested with users by placing patch [0164] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 15% on average when using this formulation as opposed to not using these patches.
  • Example 12
  • Patch [0165] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Glycine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Glycine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0166]
  • Patch [0167] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0168]
  • The above patches were tested with users by placing patch [0169] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 15% on average when using this formulation as opposed to not using these patches.
  • Example 13
  • Patch [0170] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 150 mg of L-Isoleucine, 150 mg of L-Leucine and 150 mg of L-Valine are added to 30 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the amino acid solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0171]
  • Patch [0172] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0173]
  • The above patches were tested with users by placing patch [0174] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 25% on average when using this formulation as opposed to not using these patches.
  • Example 14
  • Patch [0175] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Methionine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Methionine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0176]
  • Patch [0177] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0178]
  • The above patches were tested with users by placing patch [0179] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches.
  • Example 15
  • Patch [0180] 400 of the invention having Left-Handed molecules may be manufactured with the following specifications:
  • 500 mg of L-Taurine is added to 15 ml of distilled water; A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the L-Taurine solution so as to saturate the fabrics with the solution. The saturated fabric disks are then sandwiched and placed between separate layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0181]
  • Patch [0182] 400 of the invention having Right-Handed molecules may be manufactured with the following specifications:
  • Honey in its raw form (Sioux Honey) and unsulphured Molasses (Grandma Molasses) is utilized as the patch ingredient. The ratio of Honey to Molasses is 3 lb. of honey by weight to 355 ml of Molasses. A Pellon 100% polyester interfacing material is cut to a 1″ diameter disk; GBC Heat Laminating films (# 3000038 clear polyester substrate with homopolymer adhesive) are cut to 1.69″ in diameter. Two pieces of the interfacing material are dipped in the Honey/Molasses solution so as to saturate the fabric with the solution. The honey/molasses-saturated fabric disks are then sandwiched and placed between layers of the heat laminating film (the saturated disks are separated from one another by plastic films), and the structure is sealed with a heating surface so as to form the completed structure. [0183]
  • The above patches were tested with users by placing patch [0184] 400 having Left-Handed molecules on the right arms and patch 400 having Right-Handed molecules on the left arms; it was found that when using a hand dynamometer there was an average 10% increase in hand strength when using these patches as opposed to not using them. In other tests it was found that strength endurance (stamina) was increased over 20% on average when using this formulation as opposed to not using these patches.
  • Example 16
  • The invention provides a new supplement and method for the improvement of athletic performance, and more particularly a means by which an individual may increase their net stamina/strength endurance output. To quantitatively assess the effectiveness of the invention in improving the bench press performance of fatigued college football athletes during team training, a double-blind placebo controlled study was implemented at Morehouse College in Atlanta, Ga., with 44 college athletes from the school's football team volunteering to participate in this study. In most evaluations of strength endurance involving competitive athletes, it is common and customary to perform both baseline and comparative tests prior to the athlete having performed any other type of physical activity. In this study, both baseline and comparative data were collected after the athletes had been fatigued by a 60-minute heavy weight-training workout. In addition, it was also decided to test the athletes while under heavy physical trauma. The athletes performed the workout and tests starting at 4:30 a.m. in a weight training room where the temperature was maintained in excess of 95° F. The standardized exercise that was chosen for this test was a 185 pound or 225 pound bench press. [0185]
  • Using a double-blind randomized placebo controlled study, a total of 44 subjects, ages 18 to 30 years, volunteered to participate for this study. Subjects' baseline bench press data was collected after a normal prescribed off-season football upper body 60-minute workout session. Subjects were asked to bench press a fixed weight until failure. [0186]
  • In the next session, subjects were randomized into three groups using a numbering system that labeled participants as experiment group, placebo group or control group members with 44 completing this two-session study. The placebo group was provided with dermal patches that had placebo water formula. The experimental group was provided with experimental dermal patches. The experimental dermal patches included either patch [0187] 400 having Left-Handed molecules or patch 400 having Right-Handed molecules or both. In the experimental group, patch 400 having left-handed molecules was placed on the palm side of the right forearm of the participants, and patch 400 having right-handed molecules was placed on palm side of the left forearm of the participants. In the placebo group, placebo dermal patches were placed on palm sides of both the left arm and the right arm of the participants. A collection team independent of the players collected and monitored data throughout the study process.
  • Data collected from the two-day study was as follows. All numbers listed are repetitions performed: [0188]
    CONTROL GROUP PLACEBO GROUP EXPERIMENT GROUP
    Baseline Comparative % Change Baseline Comparative % Change Baseline Comparative % Change
    6 4 −33 8 8 0 12 10 −17
    10 12 20 7 8 14 1 3 200
    9 11 22 5 6 20 6 12 100
    5 5 0 4 3 −25 4 6 50
    12 12 0 6 3 −50 2 3 50
    10 10 0 15 18 20 5 3 −40
    10 9 −10 12 10 −17 9 9 0
    2 3 50 11 13 18 11 15 36
    3 0 −100 12 12 0 3 4 33
    4 4 0 7 10 43 18 16 −11
    10 12 20 16 21 31 15 16 7
    5 4 −20 20 23 15 6 9 50
    10 9 −10 9 7 −22 16 16 0
    5 5 0 4 5 25
    15 15 0 8 10 25
    10 11 10
  • From the data collected in the above table, it was determined that (1) the average percentage change in strength endurance in the Control group was a decrease in performance of 3.1% from the baseline tests to the comparative tests; (2) the average percentage change in strength endurance in the Placebo group was an increase in performance of 3.6% from the baseline tests to the comparative tests; (3) the average percentage change in strength endurance in the Experiment group was an increase in performance of 33.9% from the baseline tests to the comparative tests. [0189]
  • In addition, the data shows the following: [0190]
    CONTROL GROUP PLACEBO GROUP EXPERIMENT GROUP
    Decrease Same Increase Decrease Same Increase Decrease Same Increase
    5 6 5 4 2 7 3 2 10
  • In the Control group, applicants found that 31.25% of the participants showed a decrease in performance during the two-day study, 37.5% of the participants maintained the same level of performance during the two-day study, and 31.25% of the participants showed an increase in performance during the two-day study. In the Placebo group, applicants found that 30.8% of the participants showed a decrease in performance during the two-day study, 15.4% of the participants maintained the same level of performance during the two-day study, and 53.8% of the participants showed an increase in performance during the two-day study. In the Experiment group, applicants found that 20% of the participants showed a decrease in performance during the two-day study, 13.33% of the participants maintained the same level of performance during the two-day study, and 66.67% of the participants showed an increase in performance during the two-day study. [0191]
  • After removing the data for the individuals who both decreased in performance and maintenance the same level of performance, applicants found that (1) in the Control group, with respect to the 5 individuals who did show an improvement in performance from the baseline to the comparative test, the average increase in strength endurance was 24.4%; (2) in the Placebo group, with respect to the 7 individuals who did show an improvement in performance from the baseline to the comparative test, the average increase in strength endurance was 23%; (3) in the Experimental group, with respect to the 10 individuals who did show an improvement in performance from the baseline to the comparative test, the average increase in strength endurance was 57.6%. [0192]
  • After removing the data for the individuals who both increased in performance and maintained the same level of performance, applicants found that (1) in the Control group, with respect to the 5 individuals who decreased in performance from the baseline to the comparative test, the average decrease in strength endurance was 34.6%; (2) in the Placebo group, with respect to the 4 individuals who decreased in performance from the baseline to the comparative test, the average decrease in strength endurance was 28.5%; (3) in the Experiment group, with respect to the 3 individuals who decreased in performance from the baseline to the comparative test, the average decrease in strength endurance was 22.67%. [0193]
  • Based on the data collected, it is evident that there are several distinct differences in athletic performance between the three test groups. With respect to the simple averaging of performance numbers, it is not unusual that the Control group experienced a decrease in strength endurance given the nature of the test (baseline data collected on a Monday and comparative data collected on a Thursday; data collected after athletes were fatigued). With respect to the Placebo group, a case could be made that there was indeed a “Placebo effect” that took place; athletes that wore the patch product thought that they had the real technology so, hence, they made more of an effort to perform. Given the data of the average group performance improvement of 3.6%, this would be a reasonable spread in terms of attainable improvements from the baseline day to the comparative day. With respect to the Experiment group, a case could be made that there was indeed a significant effect of the experimental dermal patch on athletic performance; athletes that wore the patch product experienced an average improvement of 33.9% in strength performance. The spreads in average performance numbers between the three groups is significant and would tend to indicate that the experimental dermal patch played an important role in improving strength endurance in the experiment group. [0194]
  • Another indicator that the experimental dermal patch was having a significant effect on athletic stamina is evidenced in the chart. As could be expected, in the Control group, there is an almost even distribution between athletes that decreased in performance, athletes that remained the same in performance, and athletes that improved in performance. In the Placebo group, 7 individuals improved in performance as compared to 5 in the Control group. However, given the low average improvement in members and the well-known “Placebo effect,” this spread is anticipated. In the Experiment group, only 3 members decreased in performance, with 10 members improving in strength endurance. Given that the Experiment group had the highest percentage of members who recorded an improvement in performance, with two-thirds of the members demonstrating an improvement, and that the average improvement was significantly higher than the other two groups (33.9%), this would again indicate that the experimental dermal patch was having a beneficial effect on athletic performance. Another potentially important indicator with respect to examining whether or not the experimental dermal patch was having a beneficial effect on athletic performance is found when looking at only those individuals who increased in performance or only those individuals who decreased in performance. In the Control group, applicants found that of those individuals how did show an improvement, the average gain was 24.4%; of those in the Control group who decreased in performance, the average decline in performance was 34.6%. In the Placebo group, applicants found that of those individuals who did show an improvement, the average gain was similar to the Control group at 23%; of those in the Placebo group who decreased in performance, applicants found that the average decline in performance was 28.5%. In the Experiment group, applicants found that of those individuals who did show an improvement, the average gain was more than double of the other two groups at 57.6%; of the three individuals who showed a decrease in performance, the average decline in performance was the lowest of the three groups at 22.67%. This information clearly indicates that the experimental dermal patch was having a beneficial effect on strength endurance. [0195]
  • Based on the data collected and the results obtained, it was demonstrated that the invention (i.e., experimental dermal patch) provides a method for the improvement of athletic performance, and more particularly a means by which an individual may increase their net stamina/strength endurance output. It was also demonstrated that the Experiment group using the invention (i.e., experimental dermal patch showed the highest percentage of improvement in strength endurance when averaging all members, the highest percentage of improvement in strength endurance when averaging only those members who showed an improvement, and the lowest percentage of decreased performance when averaging only those individuals who showed a decline in performance. [0196]
  • Example 17
  • The invention provides a new supplement and method for the improvement of athletic performance, and more particularly a means by which individuals may substantially increase their net strength endurance within as quickly as the first use of the product. To quantitatively assess the effectiveness of the invention in improving the bench press performance of college football athletes during team training, a double-blind placebo controlled study was implemented at Troy State University in Troy, Ala. A standardized test was selected to measure net gains in strength endurance, and in this case the exercise that was performed by all athletes was a 225 pound flat bench press. The baseline data for this test was collected on Thursday Jun. 26, 2003. The comparative data was collected on the following Wednesday Jul. 2, 2003. Athletes were divided into three groups: Control, Placebo and Test. The Control group was tested “as is” on both of these testing days. The Placebo group was given a set of patches filled with water; this group was unaware as to whether or not the patches were real or water filled. The Test group was given a set of patches of the invention; again, this group was unaware as to the contents of the patches. It should be emphasized that the athletes used the patches of the invention only once; the test was performed within 10 minutes of first applying the patches to the athletes. [0197]
  • Using a double-blind randomized placebo controlled study, a total of 25 subjects, ages 18 to 22 years, volunteered to participate for this test study. Subjects' baseline bench press data was colleted after a brief warm up period. Subjects were asked to bench press a fixed 225 pound weight until failure. In the next session, subjects were randomized into three groups using a numbering system that labeled participants as Test group, Placebo group or Control group members with 25 completing this two-session study. The Test group was provided with non-transdermal patches that included either patch [0198] 400 having Left-Handed molecules or patch 400 having Right-Handed molecules or both. In the test group, patch 400 having left-handed molecules was placed on the palm side of the right forearm of the participants, and patch 400 having right-handed molecules was placed on palm side of the left forearm of the participants. The Placebo group was provided with non-transdermal patches that contained water. In the placebo group, placebo dermal patches were placed on palm sides of both the left arm and the right arm of the participants. A collection team independent of the players collected and monitored data throughout the study process.
  • Data collected from the two-day study was as follows; all numbers listed are repetitions performed: [0199]
    CONTROL PLACEBO TEST
    Baseline Comparative {circumflex over ( )}Reps {circumflex over ( )}Percent Baseline Comparative {circumflex over ( )}Reps {circumflex over ( )}Percent Baseline Comparative {circumflex over ( )}Reps {circumflex over ( )}Percent
    10 10 0 0 23 23 0 0 3 8 +5 +166.7%
    4 6 +2   +50% 10 10 0 0 16 15 −1  −6.2%
    12 14 +2 +16.7% 7 12 +5 +71.4% 8 9 +1  +12.5%
    9 10 +1 +11.1% 21 24 +3 +14.3% 16 18 +2  +12.5%
    10 13 +3   +30% 14 8 +6 −42.8% 7 15 +8 +114.3%
    5 6 +1   +20% 10 11 +1   +10% 5 8 +3   +60%
    20 21 +1  +4.7% 26 27 +1  +3.8% 12 14 +2  +16.7%
    18 19 +1  +5.5% 11 17 +6 +54.5%
    6 5 −1 −16.7%
    18 11 −7 −38.9%
  • From the data collected in the above table, and by removing the highest and lowest scores from each group, it was determined that (1) the average percentage change in strength endurance in the Control group was an increase in performance of 8.9% from the baseline tests to the comparative tests (average 0.875 rep improvement); (2) the average percentage change in strength endurance in the Placebo group was an increase in performance of 13.8% from the baseline tests to the comparative tests (average 1.67 rep improvement); and (3) the average percentage change in strength endurance in the Test group was an increase in performance of 43.2% from the baseline tests to the comparative tests (average 2.6 rep improvement). [0200]
  • In addition, the data shows the following: [0201]
    CONTROL GROUP PLACEBO GROUP TEST GROUP
    Decrease Same Increase Decrease Same Increase Decrease Same Increase
    2 1 7 1 2 5 1 0 6
  • The above table provides the breakdown of athletes in each group as it pertains to showing whether or not an athlete showed a decrease in performance from baseline to comparative test, remained the same in performance from baseline to comparative test, or showed an increase in performance from baseline to comparative test. [0202]
  • In the Control group, Applicants found that 20% of the participants showed a decrease in performance during the two-day study, 10% of the participants maintained the same level of performance during the two-day study, and 70% of the participants showed an increase in performance during the two-day study. In the Placebo group, Applicants found that 12.5% of the participants showed a decrease in performance during the two-day study, 25% of the participants maintained the same level of performance during the two-day study, and 62.5% of the participants showed an increase in performance during the two-day study. In the Test group, Applicants found that 14.3% of the participants showed a decrease in performance during the two-day study, 0% of the participants maintained the same level of performance during the two-day study, and 85.7% of the participants showed an increase in performance during the two-day study. [0203]
  • After removing the data for the individuals who both decreased in performance and maintained the same level of performance, Applicants found that (1) in the Control group, with respect to the 7 individuals who did show an improvement in performance from the baseline to the comparative test, the average increase in strength endurance was 19.7%; (2) in the Placebo group, with respect to the 5 individuals who did show an improvement in performance from the baseline to the comparative test, the average increase in strength endurance was 30.8%; (3) in the Test group, with respect to the 6 individuals who did show an improvement in performance from the baseline to the comparative test, the average increase in strength endurance was 63.8%. [0204]
  • After removing the data for the individuals who both increased in performance and maintained the same level of performance, Applicants found that (1) in the Control group, with respect to the 2 individuals who decreased in performance from the baseline to the comparative test, the average decrease in strength endurance was 27.8%; (2) in the Placebo group, with respect to the 1 individual who decreased in performance from the baseline to the comparative test, the decrease in strength endurance was 42.8%; (3) in the Experiment group, with respect to the 1 individual who decreased in performance from the baseline to the comparative test, the decrease in strength endurance was 6.2%. [0205]
  • Based on the data collected, it is evident that there are several distinct differences in athletic performance between the three groups. With respect to the simple averaging of performance numbers, it is not unusual that all three groups experienced an increase in strength endurance given the nature of the test (athletes were in a training session for the upcoming football season). With respect to the Placebo group, a case could be made that there was indeed a “Placebo Effect” that took place; athletes that wore the patch product thought that they had the real technology so hence they made more of an effort to perform. Given the data of the average group performance improvement of the Placebo group of 13.8% (as compared to 8.9% in the Control group), this would be a reasonable spread in terms of attainable improvements from the baseline day to the comparative day. With respect to the Test group, there was indeed a significant effect of the test dermal patch on athletic performance; athletes that wore the patch product experienced an average improvement of 43.2% in strength performance. The spreads in average performance numbers between the three groups is significant and would tend to indicate that the test dermal patch played an important role in improving strength endurance in the test group. [0206]
  • Another indicator that the test dermal patch was having a significant effect on athletic stamina is evidenced in the Table. In all three groups, Applicants found that the majority of the athletes improved in performance; however, the Control group and Placebo group showed nearly identical percentages of athletes that improved, with 70% of the Control group and 62.5% of the Placebo group. By comparison in the Test group, Applicants found that 85.7% of the participants experienced an improvement in performance. Given that the Test group had the highest percentage of members who recorded an improvement in performance, with 85.7% of the members demonstrating an improvement, and that the average improvement was significantly higher than the other two groups (43.2%) this would again indicate that the test dermal patch was having a beneficial effect on athletic performance. [0207]
  • Another important indicator with respect to examining that the test dermal patch was having a beneficial effect on athletic performance is found when looking at only those individuals who increased in performance or only those individuals who decreased in performance. In the Control group, Applicants found that, of those individuals who did show an improvement, the average gain was 19.7%. In the Placebo group, Applicants found that, of those individuals who did show an improvement, the average gain was close to the Control group at 30.8%. In the Test group, Applicants found that, of those individuals who did show an improvement, the average gain was more than triple the Control group and double the Placebo group at 63.8%. This information would indicate that the test dermal patch was having a beneficial effect on strength endurance. This improvement is dramatic in that the individuals tested had only used the test dermal patch for 10 minutes prior to the test. [0208]
  • Based on the data collected and the results obtained it was demonstrated that the invention (i.e., test dermal patch) provides a method for the improvement of athletic performance, and more particularly a means by which an individual may increase their net stamina/strength endurance output. The model utilized to evaluate the technology was a double-blind placebo controlled study, with 25 college athletes from the Troy State University football team volunteering to participate in this study. In this evaluation of strength endurance involving competitive athletes both baseline and comparative tests were performed prior to any other type of physical activity. [0209]
  • It was demonstrated that the group using the invention (i.e., test dermal patch) showed the highest percentage of improvement in strength endurance when averaging all members, the highest percentage of improvement in strength endurance when averaging only those members who showed an improvement, and the lowest percentage of decreased performance when averaging only those individuals who showed a decline in performance. [0210]
  • While a particular embodiment of the present invention has been described, it is to be understood that modifications will be apparent to those skilled in the art without departing from the spirit of the invention. The scope of the invention, therefore, is to be determined solely by the following claims. [0211]

Claims (57)

    What is claimed is:
  1. 1. An apparatus for application to a subject's body to provide a beneficial biological effect for the subject, the apparatus comprising:
    at least one organic material including a Left-Handed molecule;
    at least one substrate for said at least one organic material; and
    at least one enclosure for said at least one organic material and said at least one substrate.
  2. 2. An apparatus for application to a subject's body to provide a beneficial biological effect for the subject, the apparatus comprising:
    at least one organic material including a Right-Handed molecule;
    at least one substrate for said at least one organic material; and
    at least one enclosure for said at least one organic material and said at least one substrate.
  3. 3. The apparatus of claim 1, comprising a plurality of Left-Handed molecules.
  4. 4. The apparatus of claim 2, comprising a plurality of Right-Handed molecules.
  5. 5. The apparatus of claim 1, wherein said Left-Handed molecule is capable of causing the beneficial biological effect by interacting with a thermomagnetic energy-flow within the human body.
  6. 6. The apparatus of claim 1, wherein said Left-Handed molecule is an amino acid, wherein said amino acid is selected from a group consisting of L-Alanine, L-Arginine, L-Aspargine, L-Aspartic Acid, L-Carnitine, Acetyl-L-Carnitine, L-Camitine L-Tartrate, L-Camitine Magnesium Citrate, L-Citrulline, L-Cysteine, L-Cystine, L-GABA, L-Glutamic Acid, L-Glutamine, Glutathione Peroxidase, L-Glycine, L-Histidine, Hydroxyglutamic Acid, Hydroxyproline, L-Isoleucine, L-Leucine, Norleucine, L-Lysine, L-Methionine, L-Omithine, L-Valine, L-Phenylalanine, L-Proline, L-Serine, L-Taurine, L-Threonine, L-Tryptophan, and L-Tyrosine.
  7. 7. The apparatus of claim 2, wherein said Right-Handed molecule is capable of causing the beneficial effect by interacting with a thermomagnetic energy-flow within the human body.
  8. 8. The apparatus of claim 2, wherein said Right-Handed molecule is a D-form of an amino acid, wherein said amino acid is selected from a group consisting of D-Alanine, D-Arginine, D-Aspargine, D-Aspartic Acid, D-Carnitine, Acetyl-D-Carnitine, D-Camitine D-Tartrate, D-Camitine Magnesium Citrate, D-Citrulline, D-Cysteine, D-Cystine, D-GABA, D-Glutamic Acid, D-Glutamine, D-Glutathione Peroxidase, D-Glycine, D-Histidine, D-Hydroxyglutamic Acid, D-Hydroxyproline, D-Soleucine, D-Leucine, D-Norleucine, D-Lysine, D-Metbionine, D-Ornithine, D-Valine, D-Phenylalanine, D-Proline, D-Serine, D-Taurine, D-Threonine, D-Tryptophan, and D-Tyrosine.
  9. 9. The apparatus of claim 2, wherein said Right-Handed molecule is a sugar, wherein the sugar is dextrin, dextrose, fructose, galactose, glucose, glycogen, inositol, invert sugar, lactose, levulose, maltose, molasses, sucrose, or xylose.
  10. 10. The apparatus of claim 1, wherein the Left-Handed molecule is an amino acid, wherein said amino acid is selected from a group consisting of L-Arginine, L-Camitine, Acetyl-L-Carnitine, L-Carnitine L-Tartrate, L-Carnitine Magnesium Citrate, L-Glutamine, L-Methionine, L-Ornithine, and L-Taurine.
  11. 11. The apparatus of claim 1, wherein the Left-Handed molecule is an amino acid, wherein said amino acid is selected from a group consisting of L-Carnitine, Acetyl-L-Carnitine, L-Camitine L-Tartrate, and L-Carnitine Magnesium Citrate.
  12. 12. The apparatus of claim 2, wherein the Right-Handed molecule is a sugar, wherein the sugar is in a form of high fructose corn syrup, honey, molasses or sugar cane.
  13. 13. The apparatus of claim 2, wherein the Right-Handed molecule is associated with one or more of components including honey and molasses.
  14. 14. The apparatus of claim 1, wherein said at least one substrate is polyester or cotton.
  15. 15. The apparatus of claim 2, wherein said at least one substrate is polyester or cotton.
  16. 16. The apparatus of claim 1, wherein said at least one enclosure is made of a plastic film, wherein the plastic film is selected from a group consisting of polyethylene, polypropylene, ABS, plexiglass, lexan, light polarizing film, and linear low density film.
  17. 17. The apparatus of claim 2, wherein said at least one enclosure is made of a plastic film, wherein the plastic film is selected from a group consisting of polyethylene, polypropylene, ABS, plexiglass, lexan, light polarizing film, and linear low density film.
  18. 18. The apparatus of claim 1, wherein said at least one enclosure is made of at least one of a light polarizing film and a linear low density film.
  19. 19. The apparatus of claim 2, wherein said at least one enclosure is made of at least one of a light polarizing film and a linear low density film.
  20. 20. The apparatus of claim 1, further comprising one or more adhesive portions so as to attach said apparatus on a skin surface of the subject.
  21. 21. The apparatus of claim 2, further comprising one or more adhesive portions so as to attach said apparatus on a skin surface of the subject.
  22. 22. The apparatus of claim 20, wherein said one or more adhesive portions includes a medical grade adhesive.
  23. 23. The apparatus of claim 21, wherein said one or more adhesive portions includes a medical grade adhesive.
  24. 24. The apparatus of claim 20, wherein said apparatus can be placed in a predetermined location of a human body.
  25. 25. The apparatus of claim 21, wherein said apparatus can be placed in a predetermined location of a human body.
  26. 26. The apparatus of claim 1, wherein said apparatus is embodied in a bracelet.
  27. 27. The apparatus of claim 2, wherein said apparatus is embodied in a bracelet.
  28. 28. The apparatus of claim 1, wherein said apparatus is embodied in a necklace.
  29. 29. The apparatus of claim 2, wherein said apparatus is embodied in a necklace.
  30. 30. The apparatus of claim 1, wherein said apparatus is embodied in a watch.
  31. 31. The apparatus of claim 2, wherein said apparatus is embodied in a watch.
  32. 32. The apparatus of claim 1, wherein said apparatus is embodied in a pendant.
  33. 33. The apparatus of claim 2, wherein said apparatus is embodied in a pendant.
  34. 34. The apparatus of claim 1, wherein the apparatus further comprising one or more additives for said at least one organic material, wherein said one or more additives are selected from a group consisting of Glycerin, d-calcium pantothenate, sorbitol, propylparaben, potassium sorbate, methylparaben, and Colloidal Gold.
  35. 35. The apparatus of claim 2, wherein the apparatus further comprising one or more additives for said at least one organic material, wherein said one or more additives are selected from a group consisting of Glycerin, d-calcium pantothenate, sorbitol, propylparaben, potassium sorbate, methylparaben, and Colloidal Gold.
  36. 36. The apparatus of claim 1, further comprising one or more patches, wherein said patch(s) is (are) constructed in layers, said layers including a plastic film or a light polarizing film as an enclosure, a polyester fabric as a substrate, Water, L-Camitine, Glycerin, d-calcium pantothenate, sorbitol, propylparaben, potassium sorbate, and methylparaben.
  37. 37. The apparatus of claim 2, further comprising one or more patches, wherein said patch(s) is (are) constructed in layers, said layers including a plastic film or a light polarizing film as an enclosure, a polyester fabric as a substrate, Water, L-Camitine, Glycerin, d-calcium pantothenate, sorbitol, propylparaben, potassium sorbate, and methylparaben.
  38. 38. The apparatus of claim 1, further comprising one or more patches, wherein said patch(s) is (are) constructed in layers, said layers including a plastic film or a light polarizing film as an enclosure, a polyester fabric as a substrate, honey, and molasses.
  39. 39. The apparatus of claim 2, further comprising one or more patches, wherein said patch(s) is (are) constructed in layers, said layers including a plastic film or a light polarizing film as an enclosure, a polyester fabric as a substrate, honey, and molasses.
  40. 40. A non-transdermal patch apparatus for application to a skin surface on a human subject which causes a beneficial biological effect in the subject's body comprising:
    at least one organic material including a Left-Handed molecule;
    at least one substrate for said at least one organic material; and
    at least one enclosure for said at least one organic material and said at least one substrate.
  41. 41. A non-transdermal patch apparatus for application to a skin surface on a human subject which causes a beneficial biological effect in the subject's body comprising:
    at least one organic material including a Right-Handed molecule;
    at least one substrate for said at least one organic material; and
    at least one enclosure for said at least one organic material and said at least one substrate.
  42. 42. The apparatus of claim 1, wherein the beneficial biological effect is an improvement in the subject's stamina.
  43. 43. The apparatus of claim 2, wherein the beneficial biological effect is an improvement in the subject's stamina.
  44. 44. The apparatus of claim 40, wherein the beneficial biological effect is an improvement in the subject's stamina.
  45. 45. The apparatus of claim 41, wherein the beneficial biological effect is an improvement in the subject's stamina.
  46. 46. The apparatus of claim 1, wherein the beneficial biological effect is an improvement in the subject's strength endurance.
  47. 47. The apparatus of claim 2, wherein the beneficial biological effect is an improvement in the subject's strength endurance.
  48. 48. The apparatus of claim 40, wherein the beneficial biological effect is an improvement in the subject's strength endurance.
  49. 49. The apparatus of claim 41, wherein the beneficial biological effect is an improvement in the subject's strength endurance.
  50. 50. The apparatus of claim 1, wherein the beneficial biological effect is an improvement in physical strength for the subject.
  51. 51. The apparatus of claim 2, wherein the beneficial biological effect is an improvement in physical strength for the subject.
  52. 52. The apparatus of claim 40, wherein the beneficial biological effect is an improvement in physical strength for the subject.
  53. 53. The apparatus of claim 41, wherein the beneficial biological effect is an improvement in physical strength for the subject.
  54. 54. The apparatus of claim 1, wherein the beneficial biological effect is relief from pain experienced by the subject.
  55. 55. The apparatus of claim 2, wherein the beneficial biological effect is relief from pain experienced by the subject.
  56. 56. The apparatus of claim 40, wherein the beneficial biological effect is relief from pain experienced by the subject.
  57. 57. The apparatus of claim 41, wherein the beneficial biological effect is relief from pain experienced by the subject.
US10669596 2002-09-25 2003-09-25 Biomolecular wearable apparatus Abandoned US20040057983A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US41361702 true 2002-09-25 2002-09-25
US10669596 US20040057983A1 (en) 2002-09-25 2003-09-25 Biomolecular wearable apparatus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10669596 US20040057983A1 (en) 2002-09-25 2003-09-25 Biomolecular wearable apparatus
US12915419 US8734316B2 (en) 2002-09-25 2010-10-29 Biomolecular wearable apparatus
US14287107 US9943672B2 (en) 2002-09-25 2014-05-26 Biomolecular wearable apparatus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12915419 Continuation US8734316B2 (en) 2002-09-25 2010-10-29 Biomolecular wearable apparatus

Publications (1)

Publication Number Publication Date
US20040057983A1 true true US20040057983A1 (en) 2004-03-25

Family

ID=31998188

Family Applications (3)

Application Number Title Priority Date Filing Date
US10669596 Abandoned US20040057983A1 (en) 2002-09-25 2003-09-25 Biomolecular wearable apparatus
US12915419 Active US8734316B2 (en) 2002-09-25 2010-10-29 Biomolecular wearable apparatus
US14287107 Active US9943672B2 (en) 2002-09-25 2014-05-26 Biomolecular wearable apparatus

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12915419 Active US8734316B2 (en) 2002-09-25 2010-10-29 Biomolecular wearable apparatus
US14287107 Active US9943672B2 (en) 2002-09-25 2014-05-26 Biomolecular wearable apparatus

Country Status (1)

Country Link
US (3) US20040057983A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140602A2 (en) * 2008-05-15 2009-11-19 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
US20110184356A1 (en) * 2002-09-25 2011-07-28 Lifewave Products, Llc Biomolecular wearable apparatus
US20110220817A1 (en) * 2008-08-12 2011-09-15 Moore John W Method of reducing the distortion of the electromagnetic field
WO2015016959A1 (en) * 2013-07-30 2015-02-05 Edward Ludwig Blendermann Method for increasing muscle strength
DE102009040870B4 (en) * 2009-09-09 2016-10-13 Manfred Sietz Modified colloidal noble metal for the treatment and prophylaxis of diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153407A3 (en) * 2013-03-19 2014-11-13 Genovus Biotechnologies Inc. Muscle optimization device and method
US20150005672A1 (en) * 2013-03-19 2015-01-01 Genovus Biotechnologies Inc. Muscle optimization device and method
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393350A (en) * 1993-10-08 1995-02-28 Schroeder; Jon M. Thermoelectric generator and magnetic energy storage unit
US5597976A (en) * 1993-10-08 1997-01-28 Schroeder; Jon M. Thermoelectric generator and magnetic energy storage unit with controllable electric output
US5651973A (en) * 1990-06-01 1997-07-29 The Population Council Therapeutically effective topical application of ST1435
US20020072501A1 (en) * 1999-06-17 2002-06-13 Cyr John St. Compostitions for increasing energy in vivo
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658070A (en) 1970-10-01 1972-04-25 Nicholas R Diluzio Tobacco smoke filters
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US6030950A (en) 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5204114A (en) 1992-03-30 1993-04-20 Health Maintenance Programs, Inc. Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby
US5618823A (en) 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5501238A (en) 1993-01-11 1996-03-26 Von Borstel; Reid W. Cigarette filter containing a humectant
US5389657A (en) 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
GB9303854D0 (en) 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count
US5738624A (en) 1993-06-14 1998-04-14 Zablotsky; Charles Mask for applying a magnetic flux field to facial skin
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
CA2293502A1 (en) 1997-06-04 1998-12-10 Cornell Research Foundation, Inc. Betulinol derivatives
US6177260B1 (en) 1997-07-11 2001-01-23 The Hong Kong Polytechnic University Measurement of antioxidant (reducing) power and/or antioxidant concentration
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US8617590B2 (en) 1999-01-21 2013-12-31 Edward Ludwig Blendermann Method for increasing muscle strength
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1244455B1 (en) 1999-10-29 2009-07-22 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DK1343492T3 (en) 2000-11-22 2006-03-06 Rxkinetix Inc Treatment of mucositis
US20020156340A1 (en) * 2001-02-12 2002-10-24 Blendermann Edward Ludwig Proprioceptive device that contains nutrients for the treatment of stratural diseases
DE60123209D1 (en) 2001-03-05 2006-11-02 Ivo Pera Tobacco smoke filters and composition in favor of antioxidants and minerals
US6789546B2 (en) 2001-06-26 2004-09-14 Technion Research & Development Foundation Ltd. Filters for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject
US20030055103A1 (en) 2001-07-04 2003-03-20 Horacio Heinzen Utilization of achyrocline satureoides ("Marcela") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases
US20050032708A1 (en) 2001-09-27 2005-02-10 Bush Ashley I. Modulation of physiological processes and agents useful for same
US20030147812A1 (en) 2001-12-11 2003-08-07 Friedrich Ueberle Device and methods for initiating chemical reactions and for the targeted delivery of drugs or other agents
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
CN100469776C (en) 2002-05-17 2009-03-18 奥特拉控股公司 Amelioration of the development of cataracts and other ophthalmic diseases
JP4520089B2 (en) 2002-05-31 2010-08-04 サントリーホールディングス株式会社 Ruburofusarin glycoside-containing composition
JP3842188B2 (en) 2002-08-28 2006-11-08 株式会社日立製作所 Ultrasound therapy device
US20030039697A1 (en) 2002-09-12 2003-02-27 Yi-Ju Zhao Matrices containing nitric oxide donors and reducing agents and their use
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
CA2549994A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US20050059153A1 (en) 2003-01-22 2005-03-17 George Frank R. Electromagnetic activation of gene expression and cell growth
EP1706146B1 (en) 2003-12-31 2013-08-21 K-Pax Pharmaceuticals, Inc. Nutrient compositions and use thereof for enhanced effectiveness of the immune system
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US20050271726A1 (en) 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US20060208383A1 (en) 2005-03-17 2006-09-21 Thomas Aisenbrey Low cost magnets and magnetic devices manufactured from ferromagnetic conductively doped resin-based materials
EP1868572A4 (en) 2005-03-29 2011-03-09 F Timothy Guilford Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms
US7446096B2 (en) 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US20080045448A1 (en) 2006-08-18 2008-02-21 Alan Robert Vinitsky Reversing autonomic nervous system dysfunction by potentiating methylation
CA2667052A1 (en) 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
US20080208179A1 (en) 2006-10-26 2008-08-28 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
EP2099503A4 (en) 2006-11-28 2013-11-13 Ats Biotech Inc Burn bandage
EP1982690A2 (en) 2007-04-18 2008-10-22 BIOFARMITALIA S.p.A. Device for smoothing wrinkles on human skin
EP2152629A4 (en) 2007-04-30 2010-09-22 Agency Science Tech & Res Forming crosslinked-glutathione on nanostructure
FR2915897B1 (en) 2007-05-11 2009-08-21 Lvmh Rech cosmetic composition comprising an extract of adenium obesum, its use and a cosmetic treatment method comprising the application.
JP5334448B2 (en) 2008-05-09 2013-11-06 丸善製薬株式会社 Glutathione production enhancer and agent for the prophylaxis or treatment of diseases caused by deficiency of glutathione
US8602961B2 (en) 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
US8362080B2 (en) 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651973A (en) * 1990-06-01 1997-07-29 The Population Council Therapeutically effective topical application of ST1435
US5393350A (en) * 1993-10-08 1995-02-28 Schroeder; Jon M. Thermoelectric generator and magnetic energy storage unit
US5597976A (en) * 1993-10-08 1997-01-28 Schroeder; Jon M. Thermoelectric generator and magnetic energy storage unit with controllable electric output
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US20020072501A1 (en) * 1999-06-17 2002-06-13 Cyr John St. Compostitions for increasing energy in vivo
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734316B2 (en) 2002-09-25 2014-05-27 Lifewave, Inc. Biomolecular wearable apparatus
US20110184356A1 (en) * 2002-09-25 2011-07-28 Lifewave Products, Llc Biomolecular wearable apparatus
US9943672B2 (en) 2002-09-25 2018-04-17 Lifewave, Inc. Biomolecular wearable apparatus
WO2009140602A3 (en) * 2008-05-15 2010-01-14 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
US20120165596A1 (en) * 2008-05-15 2012-06-28 David Schmidt Apparatus and Method of Stimulating Elevation of Glutathione Levels in a Subject
WO2009140602A2 (en) * 2008-05-15 2009-11-19 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
US9149451B1 (en) * 2008-05-15 2015-10-06 Lifewave, Inc. Apparatus and method of stimulating elevation of glutathione levels in a subject
US9532942B2 (en) 2008-05-15 2017-01-03 Lifewave, Inc. Apparatus and method of stimulating elevation of glutathione levels in a subject
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
US20110220817A1 (en) * 2008-08-12 2011-09-15 Moore John W Method of reducing the distortion of the electromagnetic field
DE102009040870B4 (en) * 2009-09-09 2016-10-13 Manfred Sietz Modified colloidal noble metal for the treatment and prophylaxis of diseases
WO2015016959A1 (en) * 2013-07-30 2015-02-05 Edward Ludwig Blendermann Method for increasing muscle strength

Also Published As

Publication number Publication date Type
US20110184356A1 (en) 2011-07-28 application
US8734316B2 (en) 2014-05-27 grant
US9943672B2 (en) 2018-04-17 grant
US20140276480A1 (en) 2014-09-18 application

Similar Documents

Publication Publication Date Title
Lake Neuromuscular electrical stimulation
Classen et al. Rapid plasticity of human cortical movement representation induced by practice
SPORTS Sports massage: a comprehensive review
Campbell et al. Pharmacokinetics, safety, and effects on exercise performance of L-arginine α-ketoglutarate in trained adult men
McNaughton et al. Ergogenic effects of sodium bicarbonate
Kraemer et al. Creatine supplementation: its role in human performance
Davis et al. The effectiveness of 3stretching techniques on hamstring flexibility using consistent stretching parameters
Tschentscher et al. Health benefits of Nordic walking: a systematic review
Rodgers et al. Energy expenditure during submaximal walking with Exerstriders
Knapik et al. Angular specificity and test mode specificity of isometric and isokinetic strength training
Sidhu et al. Locomotor exercise induces long-lasting impairments in the capacity of the human motor cortex to voluntarily activate knee extensor muscles
Hausswirth et al. Effects of whole-body cryotherapy vs. far-infrared vs. passive modalities on recovery from exercise-induced muscle damage in highly-trained runners
Petersen et al. The motor cortex drives the muscles during walking in human subjects
MacDougall et al. The time course for elevated muscle protein synthesis following heavy resistance exercise
WO1994002127A1 (en) A method of increasing creatine supply depot
Tessitore et al. Effects of different recovery interventions on anaerobic performances following preseason soccer training
KR100963687B1 (en) Massage machine and method using the same
Perrey et al. Neural and muscular adjustments following repeated running sprints
Teo et al. Circadian rhythms in exercise performance: implications for hormonal and muscular adaptation
Vanderthommen et al. Electrical stimulation as a modality to improve performance of the neuromuscular system
Martin et al. Effects of recovery modes after knee extensor muscles eccentric contractions
Umeda et al. Adverse effects of energy restriction on myogenic enzymes in judoists
Park et al. Increase in maximal oxygen uptake following 2-week walk training with blood flow occlusion in athletes
Zittel et al. Reboxetine improves motor function in chronic stroke
Sprod et al. The effects of walking poles on shoulder function in breast cancer survivors

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIFEWAVE PRODUCTS, LLC, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHMIDT, DAVID;REEL/FRAME:014553/0298

Effective date: 20030924

AS Assignment

Owner name: LIFEWAVE, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:LIFEWAVE CONSOLIDATION CORPORATION;REEL/FRAME:032671/0349

Effective date: 20100212

Owner name: LIFEWAVE CONSOLIDATION CORPORATION, CALIFORNIA

Free format text: MERGER;ASSIGNOR:LIFEWAVE PRODUCTS, LLC;REEL/FRAME:032659/0803

Effective date: 20100212

AS Assignment

Owner name: SOLETLUNA HOLDINGS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIFEWAVE, INC.;REEL/FRAME:045799/0586

Effective date: 20180514